ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,177.15
0.83%
Dow Jones
42,052.19
0.69%
Gold vs US Dollar
2,736.41
0.00%
Brent Oil
72.905
0.00%
Bitcoin
69,322.70
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mineralys Therapeutics Inc (MLYS) Share Price

MLYS Mineralys Therapeutics Inc

13.45
0.07 (0.52%)
01 Nov 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Mineralys Therapeutics Inc NASDAQ:MLYS NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.07 0.52 13.45 12.65 15.70 13.74 13.11 13.48 175,767 21:30:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -71.9M -1.4459 -9.27 665.34M
 Type  Size  Price  Time  Units 
 16 225 13.45 20:03:15 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore MLYS News
30/10/202412:03EDGAR2Form 8-K - Current report
30/10/202412:00GLOBEMineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
22/10/202412:00GLOBEMineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
25/09/202412:06EDGAR2Form 8-K - Current report
25/09/202412:00GLOBEMineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
13/08/202420:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/08/202420:07EDGAR2Form 8-K - Current report
Period
Draw mode
Data Downloads for MLYS

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Mineralys Therapeutics Inc Articles